Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10977901 | 0.86 | ALDH1A1 (0.33) | ALDH1A1LMNA | |
| SCHEMBL1612440 | 0.81 | ALDH1A1 (0.35) | ALDH1A1LMNA | |
| SCHEMBL1311847 | 0.81 | CYP3A4 (0.38) | CYP3A4MAPTUSP2ALDH1A1LMNA | |
| SCHEMBL29032304 | 0.77 | SRC (0.42) | ALDH1A1 | |
| SCHEMBL3267495 | 0.77 | CYP3A4 (0.31) | CYP3A4MAPT | |
| SCHEMBL3267502 | 0.77 | CYP3A4 (0.31) | CYP3A4MAPT | |
| SCHEMBL1611823 | 0.77 | TP53 (0.30) | — | |
| SCHEMBL1313257 | 0.77 | CYP3A4 (0.35) | CYP3A4MAPTUSP2ALDH1A1LMNA | |
| SCHEMBL6551606 | 0.76 | CYP3A4 (0.38) | CYP3A4MAPTUSP2ALDH1A1LMNA | |
| SCHEMBL28010690 | 0.76 | TP53 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1914229-B1 | NOVEL CERCOSPORAMIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-06-16 | — | — | EP | disclosed |
| US-20090036492-A1 | Novel Cercosporamide Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1914229-A1 | NOVEL CERCOSPORAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036492-A1 | Novel Cercosporamide Derivative | GPR119, CBR3, SLC5A2 | CYP3A4 1027/4885MAPT 4836/4885USP2 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.